← Back to Home

Divarasib prolongs survival in Phase 3 lung cancer trial, outperforming existing KRAS G12C targeted drugs

Among 338 previously treated patients with advanced lung cancer, median overall survival reached 17.7 months with divarasib, compared with 12 months in the control group. The study, which directly compared divarasib with existing targeted drugs, also showed fewer severe treatment-related side effects, although the findings have limits to their applicability.

By SURL BioNews

For patients whose lung cancer continues to progress despite prior treatment, whether a new drug can prolong life matters more than whether it temporarily shrinks tumors. Divarasib, an investigational oral targeted drug being developed by Roche, prolonged overall survival compared with existing KRAS G12C inhibitors in the Phase 3 Krascendo 1 trial, offering a new treatment possibility for patients with advanced non-small cell lung cancer harboring this mutation. The results were presented on October 25 at the European Society for Medical Oncology (ESMO) annual meeting and simultaneously published in The New England Journal of Medicine.

The randomized trial enrolled 338 patients at 151 centers in 26 countries, all with previously treated advanced or metastatic non-small cell lung cancer harboring a KRAS G12C mutation. Of these, 167 received divarasib, while the remaining 171 received the approved drugs sotorasib or adagrasib. The study’s primary endpoint was progression-free survival assessed by blinded independent central review, with overall survival among the secondary endpoints.

At a median follow-up of 14.3 months, median overall survival was 17.7 months in the divarasib group and 12 months in the control group. The hazard ratio for death was 0.56, corresponding to a 44% reduction in the relative risk of death during follow-up. This compares the survival distributions of the two groups and cannot be interpreted as every patient living an additional 5.7 months. Progression-free survival also increased from 5.7 months in the control group to 9.8 months, indicating that the survival improvement was accompanied by more durable disease control.

Tumor responses provided another layer of evidence. According to data released by MD Anderson Cancer Center, response rates were 58.4% with divarasib and 32.3% in the control group. Among patients who responded, median duration of response was 11.9 and 6.9 months, respectively. Roche added that the response rate analysis excluded 10 patients who had no measurable lesions at baseline, so these figures were not calculated using all 338 patients.

Alongside the improvement in efficacy, the proportion of patients experiencing severe treatment-related side effects was also lower, at 25% and 35% in the two groups, respectively. Roche said common treatment-related adverse events included diarrhea, nausea, vomiting, and hepatotoxicity. The lower proportion of severe side effects helps inform an assessment of the treatment’s overall value, but does not mean the new drug is without risks. The study was sponsored by Roche and its subsidiary Genentech, which should also be considered when interpreting the evidence.

The KRAS protein is involved in cell growth signaling, and the G12C mutation can disrupt normal regulation of this signaling pathway. Divarasib is designed to lock the protein carrying this mutation in an inactive state. The significance of this trial lies in its direct comparison with existing targeted drugs in the same class, showing that more effective inhibition of the same target may translate into a survival benefit. The findings apply to a specific mutation and treatment setting and cannot be generalized to all patients with lung cancer.

The study still has several limitations: it used an open-label design, meaning both physicians and patients knew the treatment assignments. Relatively few patients in the control group received adagrasib, which also limits assessments of the individual effects of the two comparator drugs. In addition, patients with untreated brain metastases were not included, and efficacy and safety in this population remain to be clarified. Divarasib remains an investigational drug. The Phase 3 results provide evidence for subsequent regulatory review, but do not mean it has been approved or can immediately replace existing therapies.

References

  1. Roche
  2. The University of Texas MD Anderson Cancer Center